National Coordinating Center (NCC) for the Polycystic Kidney Disease (PKD) Research and Translation Core Centers
国家多囊肾病 (PKD) 研究和转化核心中心协调中心 (NCC)
基本信息
- 批准号:10218161
- 负责人:
- 金额:$ 91.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-20 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAutosomal Dominant Polycystic KidneyBeliefBiological ModelsCollaborationsCommunicationCommunitiesCritical ThinkingCystCystic Kidney DiseasesDataDevelopmentDiseaseEducational ActivitiesEvaluationEventFosteringFunctional disorderFundingFunding OpportunitiesGenesGenomicsGoalsHumanInformation DisseminationInheritedInterventionJointsKidney FailureLeadershipMissionPatientsPolycystic Kidney DiseasesPositioning AttributeReagentResearchResearch PersonnelResource DevelopmentResource SharingResourcesScienceStructureTalentsTranslational ResearchTranslationsUnited States National Institutes of Healthcohesioncohortcollaborative environmenteffective therapyexperienceimprovedinnovationinsightmaterial transfer agreementnew therapeutic targetnovel therapeuticsprogramspublic health relevancesuccesssymposiumtoolweb siteweb-accessible
项目摘要
Project Summary
Polycystic Kidney Disease (PKD) is the most common inherited cause of renal failure worldwide. The genes
responsible for the most frequent forms of PKD (PKD1, PKD2 and PKHD1) were identified over the past two
decades. Progress over these years has led to improved tools for studying cyst formation and progression and
these in turn have resulted in an improved understanding of PKD pathophysiology and, most recently, an
approved therapy. Despite these advances, however, there is no intervention to halt cystic kidney disease or
its systemic manifestations and there remains a pressing need for more effective treatments. In order to
promote interdisciplinary and integrated approaches to the identification of novel therapeutic targets, an RFA
has been issued to support PKD Research and Translation Core Centers (RTCCs) whose mission will be to
develop innovative research tools. Here we establish a new National Coordinating Center (NCC) to provide
highly organized administrative support to the RTCCs. We will implement a bold, innovative and outward-
facing program that will facilitate collaboration and cohesion between the RTCCs and establish mechanisms
for sharing of reagents and expertise broadly. The National Coordinating Center will seek to invigorate and
energize research in PKD by supporting and expanding the community of PKD investigators, by promoting
data driven science and by developing educational activities that encourage open and critical thinking and
attract the brightest new talent to the study of PKD. Leadership of the National Coordinating Center will be
provided by two investigators with an in-depth understanding of the PKD field and a deep belief in the
importance of collaborative science. The NCC will support the goals of the PKD Research Consortium with the
following Aims: 1) Convene the PKD Research Consortium Steering Committee to develop the program’s
overall direction, to organize and execute program activities and to assist with broad dissemination of
information 2) Develop a multipronged communication plan including an accessible web site for disseminating
information about research resources 3) Facilitate collaboration between RTCCs by establishing a framework
for joint development of resources 4) Facilitate broad sharing of resources across the consortium 5) Develop
an educational program, including an annual scientific symposium that will encourage constructive discourse
and diverse and creative approaches to PKD science. 6) Develop, support and execute a pilot and feasibility
program that encourages new investigators (both early stage and established) to enter the field of PKD
research. 7) Provide educational programming geared toward early stage investigators to foster the
development of a new cohort of PKD researchers and leaders. In summary, the collaborative environment
fostered by the NCC will catalyze advances that we expect will result in new insights into PKD pathobiology
and new therapeutic options for patients with polycystic kidney disease.
项目摘要
多囊肾病(PKD)是世界范围内最常见的遗传性肾功能衰竭原因。基因
在过去的两年中发现了最常见的PKD形式(PKD1、PKD2和PKHD1)
几十年。这些年的进步导致了研究囊肿形成和发展的工具的改进,以及
这些反过来又导致了对PKD病理生理学的更好理解,最近,
批准的治疗方法。然而,尽管取得了这些进展,仍没有干预措施来阻止囊性肾脏疾病或
它的全身性表现,仍然迫切需要更有效的治疗。为了
促进确定新的治疗靶点的跨学科和综合方法
已经发布,以支持PKD研究和翻译核心中心(RTCC),其使命将是
开发创新的研究工具。在这里,我们建立了一个新的国家协调中心(NCC),以提供
向区域协调中心提供组织严密的行政支助。我们将实施大胆、创新、外向的--
面向将促进区域协调中心之间的协作和凝聚力并建立机制的方案
广泛分享试剂和专业知识。国家协调中心将寻求振兴和
通过支持和扩大PKD研究人员社区,通过促进
数据驱动的科学,并通过发展鼓励开放和批判性思维的教育活动
吸引最优秀的新人才加入到PKD的研究中。国家协调中心的领导将是
由两名调查人员提供,他们对PKD领域有深入的了解,并对
协作科学的重要性。NCC将支持PKD研究联盟的目标,
以下目标:1)召开PKD研究联盟指导委员会,以制定该计划的
总体指导,组织和执行方案活动,并协助广泛传播
信息2)制定多管齐下的传播计划,包括一个可访问的网站,用于传播
关于研究资源的信息3)通过建立框架促进区域合作伙伴之间的合作
为了联合开发资源4)促进财团之间的资源广泛共享5)开发
教育计划,包括一年一度的科学研讨会,将鼓励建设性的讨论
以及对PKD科学的多样化和创造性的方法。6)开发、支持和执行试点和可行性
鼓励新的研究人员(包括早期和成熟的)进入PKD领域的计划
研究。7)提供针对早期调查人员的教育方案,以培养
发展一批新的PKD研究人员和领导者。总而言之,协作环境
由NCC培育的将催化进展,我们预计将导致对PKD病理生物学的新见解
以及多囊肾病患者的新治疗选择。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Terry J Watnick其他文献
Terry J Watnick的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Terry J Watnick', 18)}}的其他基金
Maryland Polycystic Kidney Disease Research and Translation Core Center (MPKD-RTCC)
马里兰州多囊肾病研究与转化核心中心 (MPKD-RTCC)
- 批准号:
10693919 - 财政年份:2020
- 资助金额:
$ 91.15万 - 项目类别:
Maryland Polycystic Kidney Disease Research and Translation Core Center (MPKD-RTCC)
马里兰州多囊肾病研究与转化核心中心 (MPKD-RTCC)
- 批准号:
10231255 - 财政年份:2020
- 资助金额:
$ 91.15万 - 项目类别:
National Coordinating Center (NCC) for the Polycystic Kidney Disease (PKD) Research and Translation Core Centers
国家多囊肾病 (PKD) 研究和转化核心中心协调中心 (NCC)
- 批准号:
10687258 - 财政年份:2020
- 资助金额:
$ 91.15万 - 项目类别:
Maryland Polycystic Kidney Disease Research and Translation Core Center (MPKD-RTCC)
马里兰州多囊肾病研究与转化核心中心 (MPKD-RTCC)
- 批准号:
10058976 - 财政年份:2020
- 资助金额:
$ 91.15万 - 项目类别:
National Coordinating Center (NCC) for the Polycystic Kidney Disease (PKD) Research and Translation Core Centers
国家多囊肾病 (PKD) 研究和转化核心中心协调中心 (NCC)
- 批准号:
10058889 - 财政年份:2020
- 资助金额:
$ 91.15万 - 项目类别:
Administrative Supplement to Watnick U54DK126114
Watnick U54DK126114 的行政补充
- 批准号:
10688699 - 财政年份:2020
- 资助金额:
$ 91.15万 - 项目类别:
Maryland Polycystic Kidney Disease Research and Translation Core Center (MPKD-RTCC)
马里兰州多囊肾病研究与转化核心中心 (MPKD-RTCC)
- 批准号:
10456638 - 财政年份:2020
- 资助金额:
$ 91.15万 - 项目类别:
相似海外基金
Immune Cell and Epithelial Cell Interactions in Autosomal Dominant Polycystic Kidney Disease
常染色体显性多囊肾病中免疫细胞和上皮细胞的相互作用
- 批准号:
10749617 - 财政年份:2023
- 资助金额:
$ 91.15万 - 项目类别:
Mechanisms driving Autosomal Dominant Polycystic Kidney Disease: The novel role of the RNA-binding protein ANKHD1.
常染色体显性多囊肾病的驱动机制:RNA 结合蛋白 ANKHD1 的新作用。
- 批准号:
MR/T04201X/2 - 财政年份:2023
- 资助金额:
$ 91.15万 - 项目类别:
Fellowship
CRISPR-Cas Editing as a Genetic Cure for Autosomal Dominant Polycystic Kidney Disease
CRISPR-Cas 编辑作为常染色体显性多囊肾病的基因治疗
- 批准号:
10822502 - 财政年份:2023
- 资助金额:
$ 91.15万 - 项目类别:
Modulation of cyst growth in renal tissue from patients with autosomal dominant polycystic kidney disease in a human tissue-based 3D-in-vivo-model
基于人体组织的 3D 体内模型中常染色体显性多囊肾病患者肾组织囊肿生长的调节
- 批准号:
496538332 - 财政年份:2022
- 资助金额:
$ 91.15万 - 项目类别:
Research Grants
Mechanisms driving cardiac dysfunction in Autosomal Dominant Polycystic Kidney Disease
常染色体显性多囊肾病心脏功能障碍的驱动机制
- 批准号:
10443441 - 财政年份:2022
- 资助金额:
$ 91.15万 - 项目类别:
WNT signaling in Autosomal Dominant Polycystic Kidney Disease
常染色体显性多囊肾病中的 WNT 信号传导
- 批准号:
10387670 - 财政年份:2022
- 资助金额:
$ 91.15万 - 项目类别:
An investigation into the functional role of the RhoGAP protein SH3BP1/ARHGAP43 in Autosomal Dominant Polycystic Kidney Disease
RhoGAP 蛋白 SH3BP1/ARHGAP43 在常染色体显性多囊肾病中的功能作用研究
- 批准号:
MR/W015579/1 - 财政年份:2022
- 资助金额:
$ 91.15万 - 项目类别:
Fellowship
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
- 批准号:
10534531 - 财政年份:2022
- 资助金额:
$ 91.15万 - 项目类别:
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
- 批准号:
10684097 - 财政年份:2022
- 资助金额:
$ 91.15万 - 项目类别:
WNT signaling in Autosomal Dominant Polycystic Kidney Disease
常染色体显性多囊肾病中的 WNT 信号传导
- 批准号:
10609804 - 财政年份:2022
- 资助金额:
$ 91.15万 - 项目类别:














{{item.name}}会员




